Scientific article
Open access

ILC2s: new actors in tumor immunity

Published inFrontiers in Immunology, vol. 10, 2801
Publication date2019

Innate lymphoid cells (ILCs) represent the most recently identified family of innate lymphocytes that act as first responders, maintaining tissue homeostasis and protecting epithelial barriers. In the last few years, group 2 ILCs (ILC2s) have emerged as key regulators in several immunological processes such as asthma and allergy. Whilst ILC2s are currently being evaluated as novel targets for immunotherapy in these diseases, their involvement in tumor immunity has only recently begun to be deciphered. Here, we provide a comprehensive overview of the pleiotropic roles of ILC2s in different tumor settings. Furthermore, we discuss how different therapeutic approaches targeting ILC2s could improve the efficacy of current tumor immunotherapies.

Affiliation Not a UNIGE publication
Citation (ISO format)
ERCOLANO, Giuseppe et al. ILC2s: new actors in tumor immunity. In: Frontiers in Immunology, 2019, vol. 10, p. 2801. doi: 10.3389/fimmu.2019.02801
Main files (1)
Article (Published version)
ISSN of the journal1664-3224

Technical informations

Creation03/11/2020 3:13:00 PM
First validation03/11/2020 3:13:00 PM
Update time03/15/2023 9:16:35 PM
Status update03/15/2023 9:16:35 PM
Last indexation05/05/2024 4:34:21 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack